Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 843

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 843
---
 | ​ |
| Restricted cash:                          | ​ | ​ | ​     | ​ |       ​ | ​ | ​ | ​ | ​                                                           | ​ |      ​ | ​ | ​ | ​ | ​                                          | ​ |      ​ | ​ | ​ | ​ | ​                                      | ​ | ​ | ​ | ​ |
| Commercial money market account           | ​ | ​ | ​     | ​ |     408 | ​ | ​ | ​ | ​                                                           | ​ |    408 | ​ | ​ | ​ | ​                                          | ​ |      — | ​ | ​ | ​ | ​                                      | ​ | — | ​ | ​ |
| Total financial assets                    | ​ | ​ | ​     | $ | 157,157 | ​ | ​ | ​ | ​                                                           | $ | 64,149 | ​ | ​ | ​ | ​                                          | $ | 93,008 | ​ | ​ | ​ | ​                                      | $ | — | ​ | ​ |

There were no purchases, sales or maturities of Level 3 financial assets and no unrealized gains or losses related to Level 3 available-for-sale marketable securities for the years ended December 31, 2023, 2022 and 2021. There were no transfers of financial assets between Levels 1, 2, or 3 classifications during the years ended December 31, 2023 and 2022. 13. Collaboration and Licensing Agreements Vifor (International) Ltd. (Vifor International) In October 2020, the Company entered into a license agreement with Vifor International, or Vifor Agreement No. 1, under which the Company granted Vifor International an exclusive license solely in the United States to use, distribute, offer for sale, promote, sell and otherwise commercialize difelikefalin injection for all therapeutic uses relating to the inhibition, prevention or treatment of itch associated with pruritus in hemodialysis and peritoneal dialysis patients in the United States. Under Vifor Agreement No. 1, the Company retains all rights with respect to the clinical development of, and activities to gain regulatory approvals of, difelikefalin injection in the United States. The Joint Commercialization Committee, or JCC, have the responsibility for overall coordination and oversight of Vifor International (and any affiliates or sublicensees). The Company’s membership on the JCC is at its sole discretion and is not its obligation. After the assignment of rights